AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin
المؤلفون المشاركون
Zhao, Jing
Cai, Junting
Wei, Jianxin
Li, Shuang
Suber, Tomeka
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-02-27
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Maintenance of pulmonary endothelial barrier integrity is important for reducing severity of lung injury.
Lysophosphatidic acid (LPA) regulates cell motility, cytoskeletal rearrangement, and cell growth.
Knockdown of LPA receptor 1 (LPA1) has been shown to mitigate lung injury and pulmonary fibrosis.
AM966, an LPA1 antagonist exhibiting an antifibrotic property, has been considered to be a future antifibrotic medicine.
Here, we report an unexpected effect of AM966, which increases lung endothelial barrier permeability.
An electric cell-substrate sensing (ECIS) system was used to measure permeability in human lung microvascular endothelial cells (HLMVECs).
AM966 decreased the transendothelial electrical resistance (TEER) value immediately in a dose-dependent manner.
VE-cadherin and f-actin double immunostaining reveals that AM966 increases stress fibers and gap formation between endothelial cells.
AM966 induced phosphorylation of myosin light chain (MLC) through activation of RhoA/Rho kinase pathway.
Unlike LPA treatment, AM966 had no effect on phosphorylation of extracellular signal-regulated kinases (Erk).
Further, in LPA1 silencing cells, we observed that AM966-increased lung endothelial permeability as well as phosphorylation of VE-cadherin and focal adhesion kinase (FAK) were attenuated.
This study reveals that AM966 induces lung endothelial barrier dysfunction, which is regulated by LPA1-mediated activation of RhoA/MLC and phosphorylation of VE-cadherin.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Cai, Junting& Wei, Jianxin& Li, Shuang& Suber, Tomeka& Zhao, Jing. 2017. AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin. Mediators of Inflammation،Vol. 2017, no. 2017, pp.1-12.
https://search.emarefa.net/detail/BIM-1188617
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Cai, Junting…[et al.]. AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin. Mediators of Inflammation No. 2017 (2017), pp.1-12.
https://search.emarefa.net/detail/BIM-1188617
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Cai, Junting& Wei, Jianxin& Li, Shuang& Suber, Tomeka& Zhao, Jing. AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin. Mediators of Inflammation. 2017. Vol. 2017, no. 2017, pp.1-12.
https://search.emarefa.net/detail/BIM-1188617
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1188617
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر